After a cooling period, US factory construction may be gearing up for another surge, according to analysts at UBS. The bank sees new semiconductor and pharmaceutical projects as the primary drivers, potentially pushing manufacturing-related construction spending back above $200 billion by the end of next year.
This comes after a notable slowdown. UBS Securities estimates that manufacturing construction spending fell by 25% to $186 billion over the past 12 months, following a boom from 2021 to 2024 that was fueled by electric vehicle, battery, and chip plants.
What's behind the expected upturn?
UBS believes the next wave of construction is already taking shape. The bank points to additional chip fabrication plants (fabs) and large-scale pharmaceutical buildouts as key contributors. There is also expected demand from general industrial and defense projects.
Policy has played a significant role in the previous cycle. UBS notes that the CHIPS and Science Act, along with other incentives, helped kick-start the earlier building spree. These government-backed programs were designed to boost domestic semiconductor manufacturing and reduce reliance on overseas production.
The recent slowdown in factory construction is part of a broader pattern. After a rapid expansion, it's common for such cycles to pause as projects are completed and companies reassess their needs. However, the underlying drivers—such as technological advancements and supply chain security—remain strong.
What it means for investors
For everyday investors, this news is a signal about the health of the manufacturing sector and the broader economy. Construction spending is a key indicator of business investment and confidence. A rebound suggests that companies are willing to commit capital to long-term projects, which can have ripple effects across the economy.
Investors might see this as a positive sign for companies involved in construction, engineering, and building materials. However, it's important to remember that these are cyclical trends, and timing the market based on such forecasts is risky.
The focus on semiconductors and pharmaceuticals highlights areas that are likely to see sustained investment. Semiconductors are critical for everything from smartphones to cars, and the push for domestic production is a strategic priority. Similarly, pharmaceutical manufacturing has become a focus, especially after the pandemic exposed vulnerabilities in global supply chains.
For those with exposure to these sectors, the outlook is generally positive. But as always, diversification and a long-term perspective are key.
Broader economic context
The factory construction data is part of a larger picture of US manufacturing. Recent reports have shown mixed signals. For instance, US factory growth cooled in August, but price pressures remained elevated. This suggests that while demand is softening, costs are still a concern.
Similarly, mixed US data has shown hiring cooling while factory orders rise, indicating a complex economic environment. Investors are closely watching these indicators for clues about the Federal Reserve's next moves.
The potential upturn in factory construction could also have implications for employment. Construction projects create jobs, both directly and indirectly, which could support consumer spending and overall economic growth.
Looking ahead
UBS's forecast is not set in stone. Many factors could influence whether the rebound materializes as expected. Interest rates, global demand, and government policy will all play a role. But the bank's analysis provides a useful framework for understanding the forces at play.
For now, the message is one of cautious optimism. The manufacturing sector may be poised for another leg up, driven by the same forces that powered the last boom. Investors would do well to keep an eye on these developments, as they could signal broader economic trends.
As always, it's wise to consider how these macro trends affect your own portfolio. While no one can predict the future, staying informed about the direction of key sectors can help you make better decisions.
